GRAL GRAIL, Inc.

Q3 2025 10-Q
Filed: Nov 13, 2025Period ending Sep 30, 2025
Health Care
Services-Medical LaboratoriesSEC EDGAR

GRAIL, Inc. (GRAL) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 13, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q3 2025 10-Q

Risk Factors

  • New risk: Samsung Investment closing uncertainty due to pending CFIUS regulatory approval and negotiation of Korea-focused collaboration agreements, affecting expected $110M proceeds
  • Updated risk: FDA LDT regulation vacated by court in March 2025, creating uncertainty in marketing authorization process and potential need to modify Galleri test configurations
+3 more insights

Get deeper insights on GRAIL, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.